Home » Akhil Parlapalli

Akhil Parlapalli

Analyst

Akhil Parlapalli is an Analyst at CBPartners.

Connect with Akhil Parlapalli

akhil.parlapalli@cbpartners.com

LinkedIn

Published Articles

Digital Health (pt 2): New Medical Technologies and Clinical Trials

COVID-19 (Pt 3): Testing

The final episode of the COVID-19 trilogy focuses on testing. Specifically, the different types of tests available for COVID-19 and the regulatory environment in which these tests exist.

Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?

Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners' blog post investigates this impact and explores mitigation strategies.

CBPartners’ Pharma Take-Away: COVID-19 (Pt 2): Promising Treatments in Development

In Part 2 of the COVID-19 series, healthcare consultant Jared Wolff is again joined by Matthew Rube and Akhil Parlapalli from CBPartners’ New York office to discuss some of the most promising treatments that are currently being put to the test against COVID-19.

CBPartners’ Pharma Take-Away: COVID-19 (Pt 1): Roundtable

In this episode, Jared Wolff is joined by Matthew Rube and Akhil Parlapalli from CBPartners' New York office to discuss some of the topics surrounding the novel coronavirus (COVID-19) pandemic: